Chlorpromazine for schizophrenia: A cochrane systematic review of 50 years of randomised controlled trials

BMC Medicine

Volumn 3, Issue , 2005, Pages

  Adams, Clive Elliott ^a   Rathbone, John ^a   Thornley, Ben ^a   Clarke, Mike ^b   Borrill, Jo ^c   Wahlbeck, Kristian ^d   Awad, A George ^e  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UK COCHRANE CENTRE   (United Kingdom)

^c National Probation Service   (United Kingdom)

^d VAASA CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; PLACEBO; NEUROLEPTIC AGENT;

AGRANULOCYTOSIS; AKATHISIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONSTIPATION; DEVELOPING COUNTRY; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG MEGADOSE; DYSTONIA; EMBASE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EYE DISEASE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INFORMATION PROCESSING; INFORMATION RETRIEVAL; JAUNDICE; LEUKOPENIA; MEDLINE; META ANALYSIS; MOTOR DYSFUNCTION; OUTCOMES RESEARCH; PARKINSONISM; PHOTOSENSITIVITY; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; WORLD HEALTH ORGANIZATION; XEROSTOMIA; ADOLESCENT; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 27744449274     PISSN: 17417015     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-3-15     Document Type: Review

References (30)

1. WHO: Essential Medicines 13th edition. WHO Model List 2003. http://www.who.int/medicines/organization/par/edl/expcom13/eml13_en.pdf.
2. WHO: Global Health Statistics Online, 1998. http://www.who.ch/msa/mnh/ems/rates/schizo.htm.
3. Wysowski DK, Baum C: Antipsychotic drug use in the United States, 1976-1985. Arch Gen Psychiatry 1989, 46: 929-932.
4. Burgess S: Emergency drug treatment of disturbed psychotic patients. Auditorium 1997, 6: 28-30.
5. Norquist G, Hyman SE: Advances in understanding and treating mental illness: implications for policy. Health Aff 1999, 18: 32-47.
6. Odejide AO, Ban TA: Psychotropic drug prescription pattern in a developing country (Nigeria). The need for an essential psychotherapeutic drug list. Int Pharmacopsychiatry 1982, 17: 163-169.
7. Chong MY, Tan CH , Fujii S, S Yang, Ungvari GS, Si T, Chung EK, Sim K, Tsang HY, Shinfuku N: Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004, 58: 61-67.
8. Prescription Pricing Authority: NHS 2003. http://www.ppa.org.uk/index.htm.
9. Adams CE, Bartsch S, Fenton M: Publishing patterns of the four drugs most commonly reported in schizophrenia trials. Schizophr Res 2004, 67: 268.
10. Cook RJ, Sackett DL: The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995, 310: 452-454.
11. Cole JO, Davis JM: Antipsychotic drugs. In The Schizophrenic Syndrome. New York: Grune & Stratton; 1969: 478-568.
12. Thornley B, Rathbone J, Adams CE, Awad G: Chlorpromazine versus placebo for schizophrenia. Cochrane Database Systematic Review 2004, CD000284.
13. Clarke M, Oxman AD: The Cochrane Reviewers Handbook 4.2.0. The Cochrane Library 2003, 2.
14. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7: 177-188.
15. Altman DG, Bland JM: Detecting skewness from summary information. BMJ 1996, 313: 1200.
16. Hine FR: Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic. J Nerv Ment Dis 1958, 127: 220-227.
17. Letemendia F, Harris AD: Chlorpromazine and the untreated chronic schizophrenic: a long-term trial. Br J Psychiatry 1967, 113: 950-958.
18. Hamill WT, Fontana AF: The immediate effects of chlorpromazine in newly admitted schizophrenic patients. Am J Psychiatry 1975, 132: 1023-1026.
19. Tetreault L, Bordeleau JM, Gauthier R, Vulpe M, Lapointe L: Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients. Dis Nerv Syst 1969, 30:74-84.
20. Hall RA, Dunlap DJ: A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics. J Nerv Ment Dis 1955, 122: 301-314.
21. Cole JO, Goldberg SC, Klerman GL National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group: Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964, 10:246-261.
22. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995, 273: 408-412.
23. Grygier P, Waters MA: Chlorpromazine used with an intensive occupational therapy program. Arch Neuro Psychiatr 1958, 79: 697-705.
24. Clark M, Dubowski K, Colmore J: The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther 1970, 11: 883-889.
25. Payne P: A comparison of trifluopromazine, chlorpromazine and a placebo in twenty-one chronic schizophrenic patients. Manit Med Rev 1960, 196-198.
26. Prien R, Cole JO: High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968, 18: 482-495.
27. Reschke RW: Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Dis Nerv Syst 1974, 35: 112-115.
28. Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR: Evaluation of trifluperidol in chronic schizophrenia. Psychopharmacologia 1968, 12: 193-203.
29. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315: 629-634.
30. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962, 10: 799-812.